Four Arms, and Where the Participants Went

What the trial is

A Phase 3a, 68-week, multicentre, double-blind trial in adults without diabetes with a BMI of 30 or higher, or 27 or higher with at least one obesity-related complication. It is both placebo-controlled and active-controlled, which is less common than it sounds and is the most interesting thing about it. Participants were randomly assigned in a 21:3:3:7 ratio to the combination of semaglutide 2.4 mg with cagrilintide 2.4 mg, to semaglutide 2.4 mg alone, to cagrilintide 2.4 mg alone, or to placebo, with lifestyle intervention for all groups. The dose arms described here are facts about a registered trial conducted under clinical supervision.

The headline result

3,417 participants were randomised: 2,108 to cagrilintide-semaglutide, 302 to semaglutide, 302 to cagrilintide and 705 to placebo. The estimated mean percent change in body weight from baseline to week 68 was -20.4% with the combination against -3.0% with placebo, an estimated difference of -17.3 percentage points with a 95% confidence interval of -18.1 to -16.6. Effect estimates used the treatment-policy estimand, consistent with the intention-to-treat principle - which is the more conservative of the two estimands usually reported and is worth noting, because a great many headline figures in this field are efficacy-estimand numbers.

The allocation ratio is the design decision worth examining

Twenty-one parts to the combination, three to each monotherapy, seven to placebo. That means the two arms which could establish whether the combination beats its own components - semaglutide alone and cagrilintide alone - received 302 participants each, against 2,108 for the combination. The co-primary endpoints are framed against placebo, not against the components. This is a defensible and standard choice: a registration trial's job is to demonstrate efficacy against placebo, and precision on that comparison is what the regulator asks for. It is also the reason the trial's most scientifically interesting comparison is its least powered one, and why the abstract reports the placebo comparison in detail and the monotherapy arms not at all.

What the monotherapy arms nevertheless buy

Their presence at all is unusual and valuable. Most fixed-dose combination programmes never randomise anyone to the components, which leaves the contribution of each ingredient permanently unmeasured. Having 302 participants on semaglutide alone within the same trial, same protocol, same sites and same period removes every cross-trial confounder from the comparison, even if it does not supply great precision. It is a far better basis for the question than comparing this trial's combination arm with a different trial's semaglutide arm, which is what the alternative would be.

Tolerability, stated with its comparator

Gastrointestinal adverse events affected 79.6% of the cagrilintide-semaglutide group and 39.9% of the placebo group - nausea, vomiting, diarrhoea, constipation or abdominal pain, described as mainly transient and mild to moderate in severity. Four in five is a high figure and it needs its placebo comparator to be read properly: two in five participants receiving nothing also reported gastrointestinal events, which is what happens when a trial systematically asks 3,417 people about their digestion for 68 weeks.

Where it sits now

REDEFINE 1 and REDEFINE 2 are the trials underpinning the CagriSema application submitted to the FDA. The registry lists REDEFINE 1 as active but not recruiting, with primary completion on 30 October 2024, which reflects an ongoing extension after the primary readout rather than an unfinished trial. CagriSema is not licensed in any jurisdiction at the time of writing. Semaglutide is a licensed prescription medicine; nothing supplied on this site is a version of it or an alternative to it.

Quick reference